We are taking a short break, but we will be back next week. Stay tuned!
|Bid||1.0100 x 1800|
|Ask||1.0400 x 2200|
|Day's Range||1.0100 - 1.0400|
|52 Week Range||0.7500 - 2.9400|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 03, 2021 - Nov. 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Appointment of New Director with Significant Experience in Drug Development, Licensing and CommercializationSAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Dr. De
NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Lifshitz Law Firm, P. (NASDAQ:ACRX)Lifshitz Law Firm, P.
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?